Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Aug 22;12(8):2003-16.
doi: 10.3390/12082003.

Synthesis of novel derivatives of 4-amino-3-(2-furyl)-5-mercapto-1,2,4-triazole as potential HIV-1 NNRTIs

Jingde Wu  1 , Xinyong Liu, Xianchao Cheng, Yuan Cao, Defeng Wang, Zhong Li, Wenfang Xu, Christophe Pannecouque, Myriam Witvrouw, Erik De Clercq
Affiliations

Synthesis of novel derivatives of 4-amino-3-(2-furyl)-5-mercapto-1,2,4-triazole as potential HIV-1 NNRTIs

Jingde Wu et al. Molecules. .

Abstract

A series of 5-alkylthio (2a-d), 4-arylideneamino (3a-d) and 4-arylideneamino-5-alkylthio derivatives (4a-f) of 4-amino-3-(2-furyl)-5-mercapto-1,2,4-triazole (1) were synthesized by alkylation of the parent compound with alkyl halides and condensation with aldehydes, respectively. Sulfanyl dimers 5a-d and 4-iminomethyl dimer 6 were correspondingly prepared by reaction with alkane dibromides and 1,4-diformylbenzene. Mannich base 7 was also synthesized by aminomethylation of the 3-sulfanyltriazole 1 at the N1 position. The newly designed and synthesized substituted s-triazole derivatives were assayed for anti-HIV-1 activity by examination of their inhibition of HIV-1-induced cytopathogenicity in MT-4 cells and by determination of their inhibitory effect on HIV-1 reverse transcriptase. Compound 4e was found to be the most active inhibitor against HIV-1 replication in cell culture (EC50 = 12 microM) and against HIV-1 reverse transcriptase (IC50 = 43.5 microM), which provided a good lead for further optimization.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Scheme 1
Scheme 1
Scheme 2
Scheme 2
Scheme 3
Scheme 3
Scheme 4
Scheme 4
Scheme 5
Scheme 5
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. De Clercq E. Antiviral drug discovery and development: where chemistry meets with biomedicine. Antivir. Res. 2005;67:56–75. doi: 10.1016/j.antiviral.2005.05.001. - DOI - PubMed
    1. Zhou Z., Lin X., Madura J. D. HIV-1 RT nonnucleoside inhibitors and their interaction with RT for antiviral drug development. Infect. Disord. Drug Targets. 2006;6:391–413. doi: 10.2174/187152606779025833. - DOI - PubMed
    1. Wainberg M. A., Sawyer J. P., Montaner J. S., Murphy R. L., Kuritzkes D. R., Raffi F. Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection. Antivir. Ther. 2005;10:13–28. - PubMed
    1. Di Santo R., Costi R., Artico M., Miele G., Lavecchia A., Novellino E., Bergamini A., Cancio R., Maga G. Arylthiopyrrole (AThP) derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors: synthesis, structure-activity relationships, and docking studies (part 1) Chem. Med. Chem. 2006;1:1367–1378. doi: 10.1002/cmdc.200600119. - DOI - PubMed
    1. De La Rosa M., Kim H. W., Gunic E., Jenket C., Boyle U., Koh Y. Tri-substituted triazoles as potent non-nucleoside inhibitors of the HIV-1 reverse transcriptase. Bioorg. Med. Chem. Lett. 2006;16:4444–4449. doi: 10.1016/j.bmcl.2006.06.048. - DOI - PubMed

Publication types

MeSH terms